Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society Congress
Capricor said its HOPE-3 extension analysis showed patients who switched from placebo to deramiocel slowed upper-limb decline by 76% over the following year. The result adds a longer-duration clinical readout as the Duchenne program moves toward further regulatory and development milestones.
Capricor Therapeutics presented a 24-month crossover analysis from the open-label extension of its HOPE-3 study at the 2026 World Muscle Society Congress. Patients who began deramiocel after spending a year on placebo slowed upper-limb decline by 76% compared with their own prior year.
The analysis follows the study's placebo-controlled period and extends the observation window to two years, allowing the company to compare each patient's decline before and after switching treatment. It concerns upper-limb function in Duchenne muscular dystrophy, a disease in which maintaining arm function is clinically important as weakness progresses.
The result directly affects Capricor's deramiocel program and its development path in Duchenne muscular dystrophy. The company presented the findings as an open-label extension analysis, so the treatment comparison is based on patients' prior performance rather than a concurrently randomized placebo group.
The next read on the program will depend on how regulators and clinicians assess the durability and design of the evidence, including the crossover structure and the use of patients' own prior year as the comparison. Further company updates and regulatory milestones should clarify how the 24-month findings fit into the program's path forward.
CAPR patients switching from placebo to deramiocel slowed upper-limb decline by 76% over the next year.
The 76% within-patient slowing gives Capricor a concrete efficacy signal for deramiocel, but the open-label crossover design makes the durability and regulatory weight of the result the key constraint. Company-specific positioning cannot be tightened from the clinical result alone without a dated forward milestone.
A subsequent clinical or regulatory update could show weaker durability or limit the significance of the open-label, within-patient comparison.
CoverageSource: GlobeNewswire · Published here MON, OCT 5 · 9:00 AM ET · the only report in this recordHow this is decided →
Earlier context and later coverage are dated relative to this report. Automatically linked reports may cover a broader event.
No later reports linked yet.
Follow this story to find new evidence in your Following desk.
The 24-month analysis found a 76% slowing in upper-limb decline after patients switched from placebo to deramiocel, supporting a durable functional benefit in Duchenne muscular dystrophy.
The comparison uses each patient's prior year rather than a concurrent randomized control group, leaving the clinical and regulatory interpretation less definitive.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →